MedTrace Logo

Phase II Two-step Radioimmunotherapy Clinical Study in Medullary Thyroid Carcinoma

NCT00467506 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL

Last updated 2011-11-11

No results posted yet for this study

Summary

Phase II clinical trial assessing efficacy and toxicity of pretargeted radioimmunotherapy using anti-CEAxanti-DTPA bispecific antibody and di-DTPA-131I peptide in patients with reccurrence of medullary thyroid carcinoma (abnormal calcitonin level and biomarkers doubling time lower than 5 years)

Conditions

  • Thyroid Neoplasms

Interventions

DRUG

bispecific antibody and di-DTPA-131I

Sponsors & Collaborators

  • Nantes University Hospital

    lead OTHER

Principal Investigators

  • Francoise Bodere, MD · Nantes University Hospital

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
FACTORIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2004-05-31
Primary Completion
2011-01-31
Completion
2011-01-31

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00467506 on ClinicalTrials.gov